Background. Other than adult T-cell leukaemia (ATL) and HTLV-I associated myelopathy (HAM), the health effects of infection with human T-lymphotropic virus type I (HTLV-I) are not well defined. Method. A cohort of 201 confirmed HTLV-I seropositive Jamaican food service workers and 225 seronegative controls of similar age and sex from the same population was examined. A health questionnaire, physical examination, and laboratory tests were performed at enrolment into the cohort in [1987][1988]. Results. One of 201 HTLV-I seropositives, but no controls were diagnosed with HAM, for a prevalence of 0.5% (95% confidence interval) (Cl) 0.01-2.7%); no cases of ATL were diagnosed. While there was no difference in current symptoms, the HTLV-I seropositive group was more likely to report a past medical history of hepatitis or jaundice (OR = 3.49, 95% Cl : 0.93-13.08), malaria (OR = 2.13, 95% Cl : 0.96-4.73), and dengue fever (OR = 1.37, 95% Cl : 0.82-2.29); however, these differences were of borderline statistical significance. Low income HTLV-I seropositive women had lower body weight (P < 0.01) and body mass index (P < 0.009) than their seronegative counterparts; similar differences were seen in the smaller male group. A trend toward higher prevalence of severe anaemia (haemoglobin <10 g/dl) (12.6% versus 7.7%, P < 0.105) and a significantly lower prevalence of eosinophilia (1.0% versus 6.3%, P < 0.004) was seen among HTLV-I seropositives compared to controls. Conclusions. Although most HTLV-I seropositives are asymptomatic, HAM may be diagnosed in approximately 0.5% of carriers. Chronic HTLV-I infection may also exert subtle effects on body mass and haematological parameters.
models of age-specific HTLV-I seroprevalence and ATL incidence data have estimated that the lifetime risk of developing ATL in an HTLV-I infected child is approximately 4%, 67 and that of HAM 0.25-2.4%. 8 ' 9 However, there is little data on ATL or HAM incidence from prospective studies of those infected with HTLV-I.
Other potential pathological effects of HTLV-I include infective dermatitis, 10 uveitis," lymphocytic alveolitis, 12 arthritis, 13 polymyositis^T-S lymphoproliferative disease," and suppression of delayed hypersensitivity immune response. 16 Faster progression to AIDS in those co-infected with HTLV-I and HIV-1 17 and the infrequent occurrence of opportunistic infections 18 have also been related to infection with HTLV-I. However, several of these putative HTLV-I associations are based upon case series and the causative role of HTLV-I has not been proven. Little is known about the natural history of HTLV-I infection or immune response to the virus, and prognostic factors for the development of ATL or HAM. We therefore initiated a prospective study of Jamaican HTLV-I seropositives and seronegative controls. Clinical and laboratory data from the enrolment visit of this cohort are the subject of this report. An analysis of risk factors for seropositivity in the same cohort is reported in the companion article. 19 
METHODS

Study Population
Detailed methods by which the cohort of seropositives and seronegative controls was selected are published in the companion article. 19 In brief, all 284 seropositive individuals from two parishes (Kingston/St Andrew and Clarendon) in a 1985-1986 Jamaican HTLV-I seroprevalence survey were frequency matched for age, sex, and parish with an equal number of seronegatives from the same survey. Using information from the previous serological survey, letter, telegrams or personal visits were used to enrol the 568 targeted individuals during 1987-1988. Interviews and examinations for this enrolment visit were performed at local health centres with both the subject and the examiner blinded as to HTLV-I status. Following the administration of a questionnaire on current symptoms and past medical history, the trained nurse interviewers performed a screening physical examination directed at the skin, lymph nodes and nervous system. At the end of the visit, HTLV-I test results were communicated to the subjects, and HTLV-I seropositives were given information on possible health effects of HTLV-I and counselled on ways to prevent secondary transmission of the virus. Subjects with significant neurological or haematological (fevers, night sweats, lymphadenopathy) complaints, or specific abnormal findings on screening physical examination, were referred for medical evaluation by an internist (RW) and, if warranted, by a neurologist (OSM) with extensive experience in the diagnosis and care of patients with HAM. 20 The study protocol was approved by the relevant review committees of the National Cancer Institute, the University of the West Indies, and the Jamaican Ministry of Health.
Laboratory Testing
HTLV-I serological testing of samples from the 1987-1988 enrolment visit was performed using an enzyme linked immunosorbent assay for HTLV-I antibody (Dupont, Wilmington DE) and Western immunoblot (Cambridge Biotech, Rockville MD) methods as described in the companion article. 19 For this analysis of the health outcome data, subjects who were indeterminate in 1987-1988 were eliminated from the analysis. The seven subjects with serological results that differed between the original large scale screening and the enrolment visit were classified according to their result for the 1987-1988 visit.
Complete blood counts and serum chemistries were performed using standard automated methods at the University Hospital of the West Indies. White blood cell differential counts were done manually by trained clinical laboratory technicians. Severe anaemia was defined as a haemoglobin concentration of <10 g per 100 ml and eosinophilia as 2=500 eosinophils per cc of blood.
Statistical Analysis
Data manipulation was carried out using a statistical software program (SAS version 6.1, Cary NC) running on an IBM mainframe computer. For categorical variables, the frequency of responses were compared between seropositives and controls using crosstabulation, and differences were tested using the y} or Fisher's exact tests. Confidence interval (CI) on proportions were calculated by binomial methods. The mean and standard deviation of continuous variables were calculated for both the HTLV-I positives and the control groups, and the distributions of values for each group were compared using overlay plots. Differences in numerical variables with approximately normal distributions were tested with Student's T test; the Wilcoxon rank sum test was used to test for differences in numeric variables without a normal distribution.
RESULTS
Symptoms and Past Medical History
A total of 201 confirmed HTLV-I seropositives and 225 seronegative controls were included in this analysis (see companion article). 19 There were no significant differences in symptoms related to ATL or HAM which may have occurred within the past year (Table 1) . A past history of malaria (odds ratio (OR) = 2.13, 95% CI : 0.96-4.73), dengue fever (OR = 1.37, 95% CI : 0.82-2.29) and hepatitis or jaundice (OR = 3.49, 95% CI : 0.93-13.08), were reported more commonly by the HTLV-I seropositive group, although these findings were not quite significant at the P = 0.05 level. The possibility that a common vector was responsible for the co-prevalence of HTLV-I, malaria, dengue and hepatitis was investigated by logistic regression. Models including altitude of birthplace as a surrogate variable for mosquito exposure along with HTLV-I serostatus as predictors of each disease did not substantially change the previously noted associations (OR = 2.28, 95% CI : 0.99-5.28 for malaria; OR = 1.37, 95% CI : 0.80-2.38 for dengue fever; and OR = 3.65, 95% CI: 0.97-13.75 for hepatitis). Birthplace at an altitude of <1000 feet was associated with dengue fever (OR = 2.02, 95% CI : 1.13-3.59) but not with the other infectious diseases.
Other infectious, haemotological, dermatological, gastrointestinal, rheumatological, and neurological diseases were reported with nearly equal frequency in the two groups with the exception of a slightly higher prevalence of parasitic disease among the HTLV-I seropositives (Table 1) . Reproductive history (data not shown) was similar between female HTLV-I seropositives and controls.
Physical Examination and HAM Diagnosis
Screening physical examinations carried out in a standardized fashion by trained nurses revealed differences in anthropometric measurements consistent with lower body mass or fat content in the HTLV-I seropositive group (Table 2) . The results are stratified by both sex and income because the effect of HTLV-I status was most apparent in the low income group. Despite similar mean heights, low income HTLV-I seropositives had lower weight, body mass index, and triceps skinfold thickness than their seronegative counterparts. Although of similar magnitude in both sexes, only in the more numerous low income female group did the differences reach statistical significance for weight (P = 0.01) and body mass index (P = 0.009). The findings were similar after stratification by age (<30, 30-39, 40-49, 50-59, and 3=60), although subjects <30 had markedly lower body mass than older subjects. There were no differences in mean pulse, systolic blood pressure, or diastolic blood pressure between the seropositives and seronegatives (data not shown).
Examination of the skin was performed (Table 3 ) because ATL is frequently manifested by skin lesions caused by the infiltration of malignant lymphocytes. There were equivalent percentages of seropositives and controls with any abnormal finding on dermatological examination (9.5% versus 8.9%), and no specific type 
FIGURE 1 Frequency histograms of haematological results in a cohort of HTLV-I seropositives and controls. The percentage of subjects in each group with a particular level of laboratory result is plotted on the vertical axis for: (a) haemoglobin; (b) total white blood count (WBC); (c) absolute lymphocyte count; and (d) absolute eosinophil count.
of skin finding was more common among the seropositives. There was no difference in lymphadenopathy between the two groups. There was no difference in auditory acuity to a whispered phrase. Abnormalities in tandem gait (N = 7) and in vibratory sensation (N = 6) were the most common neurological findings, but no difference between HTLV-I seropositives and controls was observed. Seventeen subjects with abnormal screening neurological examinations by the nurses were referred to the study internist for confirmatory examination. At this stage, 13 subjects were determined to have nonneurological disease, and four subjects (one had trouble rising from a chair and three with abnormal gait) were in turn referred to the study neurologist. Of these four patients, three were diagnosed with non-neurological disease (osteoarthritis, rheumatoid arthritis and deep vein thrombosis). However, one (0.5%, 95% CI : 0.01-2.7%) of the 201 HTLV-I seropositives was diagnosed with HAM for the first time. This 45-year-old male reported that, beginning 6 months prior to his examination, he began to drag his legs and could not walk long distances. However, he could still walk with a mildly abnormal gait, and was still employed as a waiter. On examination, muscle strength was normal but there was spasticity of the lower extremities. Patellar and ankle jerk reflexes were exaggerated, and plantar reflexes were extensor. Serum VDRL was negative, serum BI2 was normal, and the sedimentation rate was normal. A myelogram showed no compression of the spinal cord. These findings are consistent with the WHO definition of HAM. 21 
Laboratory Testing and ATL Screening
There was no difference in the mean serum calcium concentration between the HTLV-I seropositives (2.38 mmol) and the controls (2.38 mmol); one asymptomatic control had a value of 3.3 mmol. The results of haematological measurements performed on the cohort are presented in Figure 1 . The distribution of haemoglobin levels showed an excess of HTLV-I seropositives in the lower tail of the distribution, with 25 (12.6%) of the seropositives compared to 17 (7.7%) of the controls having haemoglobin values of =£10, however, the difference failed to achieve statistical significance (P < 0.105, two-tailed Fisher's exact test) ( Figure 1A ). For anaemia defined according to conventional criteria of < 12.5 g/dl in men and <11.5 g/dl in women, there was no difference in the prevalence of anaemia between HTLV-I seropositives (16.6%) versus controls (14.0%). Although the mean values for the HTLV-I seropositives were slightly lower than for controls for both total white blood count (5658 versus 5956 per mm 3 ) and absolute lymphocyte count (2528 versus 2819 per mm 3 , calculated from the differential per cent), neither difference was statistically significant (P < 0.37 and 0.33, respectively, by T test) (Figures IB and 1C) .
Although the median absolute eosinophil count was 100 per mm 3 in both groups, the distribution was skewed to the right by subjects with eosinophilia, defined as an absolute count of &500 ( Figure ID) . The HTLV-I seropositive group included significantly fewer subjects with eosinophilia (2/119 or 1.0%) compared to controls (14/221 or 6.3%), a difference that was highly significant (P < 0.004 Fisher's exact test). Examination of stool specimens on a subset of the subjects from the enrolment visit revealed no significant difference in parasitic colonization of the HTLV-I seropositives compared to controls. 22 No cases of ATL were diagnosed. The frequency of large activated-appearing lymphocytes was similar between the two groups. However two (1.0%) HTLV-I seropositives but no controls have cleaved lymphocytes consistent in appearance with the 'flower cells' of ATL; these cells were present at counts of 40 and 280 per mm 3 , levels which are too low to diagnose ATL, but which are known to occur in a minority of HTLV-I seropositives. One control had a total WBC of 68 000 with an absolute lymphocyte count of 65 500 and was subsequently diagnosed with chronic lymphocytic leukaemia and another control had a WBC of 23 000 with polymorphonuclear predominance and had a perienrolment diagnosis of pneumonia. There was no difference in polymorphonuclear cell per cent or absolute count between the two groups.
DISCUSSION
The majority of HTLV-I seropositive food service employees examined at the time of enrolment into this cohort study did not have symptoms or detectable illness. One prevalent case of HAM was diagnosed, and although two HTLV-I seropositives had a low percentage of cleaved lymphocytes on peripheral blood smear, no clinical cases of ATL were diagnosed. Other interesting findings in the HTLV-I subjects included a higher lifetime prevalence of self-reported hepatitis, malaria and dengue fever; lower body weight and body mass index, particularly in low income women; and a diminished frequency of eosinophilia.
The screening neurological examination yielded a number of abnormal findings, most of which were nonspecific or due to non-neurological illness. We purposefully set a low threshold for referral from the study nurses to the supervising internist and neurologist because the onset of HAM may be insidious with subtle neurological deficits. Our approach was successful in the diagnosis of one case of HAM among 201 HTLV-I seropositives, for a prevalence of 0.5% (95% CI : 0.01-2.70%). Although this prevalence estimate is imprecise because it is based upon a single case, it may be compared to the rate of 1 in 1464 reported in HTLV-I endemic Kyushu Japan. 8 Our study included neurological screening of a cohort of seropositives, while the Japanese study was based upon active surveillance of previously diagnosed HAM cases.
The low prevalence of symptoms and past illness reported by the cohort is most likely due to their relatively young age and the occupationally-based sampling frame, which would tend to underrepresent those unable to work because of chronic illness. The fact that HTLV-I seropositivity was weakly associated with a past medical history of either dengue fever, malaria, or hepatitis may be interpreted in several ways. First, since self-reported diagnoses are subject to inaccuracy and bias, it is possible that chronic HTLV-I infection may cause symptoms that were wrongfully attributed to the above diseases. Secondly, dengue, malaria or hepatitis may be more prevalent in the social or behavioural group at increased risk of HTLV-I infection, or these diseases may have more severe clinical courses in HTLV-I infected patients, leading to a higher probability of diagnosis.
Finally, HTLV-I, dengue and malaria could share a common mode of transmission. Malaria was eradicated from Jamaica shortly after the second World War, but there had been large outbreaks of dengue fever within the 10 years previous to this study. 23 The hypothesis of vector-born transmission of HTLV-I has been raised elsewhere because of an inverse correlation of seroprevalence with elevation above sea level in Jamaica, 24 and because transmission of the closely related bovine leukaemia virus among cattle has been linked to biting flies. 25 However, another study in Jamaican food service employees found no difference in antibodies to dengue or other arboviruses between HTLV-I sero-' positives and seronegatives. seropositives in Jamaica (unpublished data), we measured height, weight and triceps skinfold thickness in this age-and sex-matched cohort. The finding of a consistent trend toward lower weight, body mass and skinfold thickness in HTLV-I seropositive men and women (Table 2) is intriguing. HTLV-I infection in vitro has been linked to the production of various cytokines including interleukin-2, 27 interleukin-9, 28 and granulocyte-macrophage colony stimulating factor. 29 It may be hypothesized that chronic HTLV-I infection, either directly or through lymphocyte activation or proliferation, causes elevated cytokine levels in vivo which in turn cause the observed effect on body mass. Because the effect was most pronounced in the low income groups, any biological effect of HTLV-I is likely to be modulated by differences in diet and physical exertion between the socioeconomic groups. The possible effect of cytokines, as well as relative deficit in fat versus muscle mass, deserve further study.
Our screening physical examination showed little difference in dermatological, lymphatic or neurological findings between HTLV-I seropositives and controls. We did not observe lesions consistent with smoldering ATL 30 nor of the 'infectious dermatitis' recently described in HTLV-I seropositive children. 10 Multiple or bulky lymphadenopathy, which is the most common presenting sign among patients with clinically diagnosed ATL, was not observed. Further follow-up of our cohort will be needed to determine whether screening for adenopathy is useful in the early diagnosis of the malignancy. 31 Clinical laboratory testing of the cohort revealed a slightly increased prevalence of severe anaemia and a significant deficit in the prevalence of eosinophilia among the HTLV-1 seropositives. Both of these findings consisted of over-(or under-) representation of the HTLV-I seropositives in the tail of the laboratory value frequency distribution, rather than a shift of the overall distribution. Since all of the cases of severe anaemia occurred in women, we cannot exclude iron deficiency as a potential confounding variable. Unfortunately we did not collect data on iron levels in the cohort. Another cohort study of HTLV-I has also documented an association between seropositivity and decreased eosinophils; 32 however, in contrast to the present report, it found a correlation between HTLV-I and higher red blood cell count. The haematological findings are plausible given the many haematological derangements associated with human immunodeficiency virus, another chronic retroviral infection. In addition, a blunted eosinophilic response could predispose to the higher prevalence of parasitic disease in HTLV-I infected patients reported by this and other studies. 33 ' 34 The results presented above are drawn from the enrolment visit of a prospective cohort study of HTLV-I seropositives and matched seronegative controls, and are subject to the limitations of any cross-sectional study. Additional observation of the cohort may help to confirm or refute the findings on HAM, body mass, anaemia and diminished eosinophilia reported here. With a median age of 40 for women and 38 for men at enrolment, the cohort will also allow the observation of the peak incidence of ATL and HAM in the fifth decade of life.
